<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05027867</url>
  </required_header>
  <id_info>
    <org_study_id>KRT-232-112</org_study_id>
    <nct_id>NCT05027867</nct_id>
  </id_info>
  <brief_title>KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer</brief_title>
  <official_title>An Open-Label, Multicenter, Phase 2 Study of the Safety and Efficacy of KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer (SCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kartos Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kartos Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the&#xD;
      treatment of patients with relapsed or refractory small cell lung cancer.&#xD;
&#xD;
      This study will be conducted in 2 parts. Part 1 will evaluate two treatment arms, each with a&#xD;
      different KRT-232 dose. Part 2 will continue the evaluation of the selected treatment arms&#xD;
      from Part 1.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">November 2025</completion_date>
  <primary_completion_date type="Anticipated">May 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR) of each arm</measure>
    <time_frame>24 weeks</time_frame>
    <description>The proportion of subjects achieving partial response or better per RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) of each arm</measure>
    <time_frame>1 year</time_frame>
    <description>Time from initiation of response to disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) of each arm</measure>
    <time_frame>1 year</time_frame>
    <description>Time from first dose to disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) of each arm</measure>
    <time_frame>1 year</time_frame>
    <description>Time from first dose to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR) of each arm</measure>
    <time_frame>24 weeks</time_frame>
    <description>The proportion of subjects achieving stable disease or better per RECIST 1.1</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Small-cell Lung Cancer</condition>
  <condition>Small Cell Lung Carcinoma</condition>
  <condition>Small Cell Lung Cancer Extensive Stage</condition>
  <condition>Small Cell Lung Cancer Recurrent</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KRT-232 240 mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KRT-232 180 mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KRT-232</intervention_name>
    <description>Administered by mouth</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>navtemadlin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of SCLC documented as TP53WT&#xD;
&#xD;
          -  Disease must be measurable per RECIST Version 1.1&#xD;
&#xD;
          -  Evidence of radiographic progression during or after at least one prior&#xD;
             platinum-containing therapy with no curative therapy available. Subjects who have&#xD;
             received only one prior line of therapy must not be candidates for platinum-based&#xD;
             regimens at relapse.&#xD;
&#xD;
          -  Subjects must have received a checkpoint inhibitor (PD-1 or PD-L1) unless&#xD;
             contraindicated if checkpoint inhibitors are approved and available.&#xD;
&#xD;
          -  ECOG â‰¤ 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Symptomatic or uncontrolled central nervous system (CNS) metastases.&#xD;
&#xD;
          -  Prior treatment with MDM2 inhibitors&#xD;
&#xD;
          -  Chemotherapy, immune therapy, cytokine therapy, or any investigational therapy within&#xD;
             14 days prior to the first dose of study treatment&#xD;
&#xD;
          -  Grade 2 or higher QTc prolongation (&gt; 480 milliseconds per NCI-CTCAE criteria, version&#xD;
             5.0)&#xD;
&#xD;
          -  History of major organ transplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>John Mei</last_name>
    <phone>650-542-0136</phone>
    <email>jmei@kartosthera.com</email>
  </overall_contact>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 25, 2021</study_first_submitted>
  <study_first_submitted_qc>August 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2021</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>navtemadlin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

